---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000689"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:34:31.186473+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology CBO Pamela Bush departing effective Feb 15, 2024

## Summary
- Pamela Bush, Ph.D., MBA, Chief Business Officer, will leave the company on Feb 15, 2024.
- Search initiated to fill CBO role, consistent with broader corporate development strategy.
- No reason for departure provided; no replacement named as of filing date.

## SEC filing metadata
- accession: 0001171843-24-000689
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184324000689/0001171843-24-000689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184324000689/f8k_020824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000689
- JSON: https://secwatch.observer/filing/0001171843-24-000689.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000689.txt

## Key facts
- Executive change
  Pamela Bush resigned as Chief Business Officer at Axe Compute Inc..
  - Action: resigned
  - Role: Chief Business Officer
  source text: On February 2, 2024, Predictive Oncology Inc. (the “Company”) and Pamela Bush, Ph.D., MBA, the Company’s Chief Business Officer, agreed that Dr. Bush will leave the Company effective February 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446159/000117184324000689/0001171843-24-000689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.